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INTRAVITREOUS RECOMBINANT TISSUE
PLASMINOGEN ACTIVATOR AND
GAS TO TREAT SUBMACULAR HEMORRHAGE IN
AGE-RELATED MACULAR DEGENERATION
San-Chang Tsai, Jane-Ming Lin, and Hsin-Yi Chen
Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan.
We evaluated the safety and efficacy of intravitreous recombinant tissue plasminogen activator (rTPA)
and gas for the treatment of submacular hemorrhage in age-related macular degeneration (ARMD). From
January 2000 to April 2002, we enrolled 15 patients with submacular hemorrhage secondary to ARMD.
All patients received 100 µg rTPA and 0.3 mL perfluoropropane intravitreously. Postoperatively, all patients
were kept in a supine position for 4 hours followed by a face-down position for 4 days. Anatomic and
functional results were evaluated during a follow-up period of 6 to 19 months. Submacular blood was
completely displaced in 12 patients (80%) and partially in three (20%). Best postoperative visual acuity
improved in all 15 eyes; in seven eyes (47%), the improvement was two or more lines. Final visual acuity
improved in 12 eyes, remained stable in two eyes, and worsened in one eye. Onset of hemorrhage within
21 days was associated with better gains of lines in best postoperative (p = 0.0256) and final visual acuity
(p = 0.044). Although two patients developed mild breakthrough vitreous hemorrhage within 1 day after
treatment, no rTPA-related retinal toxicity was observed. Intravitreous injections of rTPA and gas are safe
and effective in improving visual acuity in patients with submacular hemorrhage secondary to ARMD.
Although the final visual outcome is often limited by the progression of the disease, significant and stable
visual recovery over an extended follow-up period is possible using this easy and convenient technique.
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Submacular hemorrhage may cause acute vision loss and
has a poor prognosis for vision improvement. Age-related
macular degeneration (ARMD), presumed ocular histo-
plasmosis, retinal arterial macroaneurysm, trauma, myopia,
idiopathic submacular hemorrhage, retinal detachment,
and vitreoretinal surgery can all cause submacular
hemorrhage [1]. Submacular hemorrhage secondary to
ARMD is the most severe form, and when the lesion involves
the fovea, vision recovery becomes more difficult [2,3].
Natural history studies show that ARMD with submacular
hemorrhage has a poor prognosis for visual outcome [3–7].
Although several treatments have been evaluated for
submacular hemorrhage, visual outcome did not improve
significantly following treatment. Vitreoretinal surgery
successfully removes subretinal blood clots in the fovea [1,
8–15]. However, the potential damage to the adjacent
photoreceptors, retinal pigment epithelium, and choroids,
and the postoperative complications associated with the
procedure (i.e. retinal detachment) limit the recovery of
visual acuity.
As an alternative to surgical treatment, Herriot recently
reported treating submacular hemorrhage using intra-
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vitreous injections of recombinant tissue plasminogen
activator (rTPA) and gas [16]. The procedure resulted in a
high anatomic success rate (blood displacement in 19 of 20
eyes) and facilitated visual recovery. The encouraging initial
experience has been further substantiated by other
investigations [2,17–23]. However, racial differences in
treatment response, the optimal dose of rTPA, and the
prevention of progressive retinal degeneration following
treatment remain to be determined.
In this study, we report our experience of the safety and
efficacy of this method for managing patients with massive
submacular hemorrhage in Taiwan. After clearing the
masked fundus, causes  of submacular hemorrhage can be
accurately diagnosed and, if indicated, laser treatment for
the underlying choroidal neovascular membrane (CNVM)
can be initiated.
MATERIALS AND METHODS
Patients
From January 2000 to April 2002, we enrolled 15 consecutive
patients (4 women and 11 men; age range, 55–89 years;
mean age, 70.8 years; 15 affected eyes) seen at our hospital
with submacular hemorrhage centered in or close to the
fovea. All submacular hemorrhages were secondary to
ARMD. The Medical Ethics Committee of the China Medical
University Hospital approved the study, and written
informed consent was obtained from every patient. Patients
with a history of bleeding disorders, anticoagulant therapy,
inflammatory eye disease, or vitreous hemorrhage at the
initial examination were excluded from the study. Clinical
data were recorded prospectively on standardized forms.
All patients underwent complete ophthalmologic
examination including fluorescein angiography (FA) and
color fundus photography at initial presentation, 1 to 2
weeks after treatment, and at 2- to 4-week intervals post-
treatment. Visual acuity was determined using the Snellen
chart with manifest refraction, or the patient’s spectacle
correction and pinhole. Visual acuity of less than 20/400 on
the Snellen chart was determined by the distance at which
the patient was able to count fingers (e.g. 1/200, 2/200,
3/200) or to recognize hand motions.
Safety
Safety was determined by monitoring the patients for
ophthalmic conditions, including intraoperative and
postoperative complications and retinal toxicity. A weekly
effect report was prepared for the first month and a monthly
report thereafter. Follow-up of patients’ conditions were
assessed in the Outpatient Department (follow-up ranged
from 6 to 19 months, with a mean of 13 months).
Intravitreous injection of rTPA and gas
The procedure was performed in an outpatient setting with
the patient under retrobulbar anesthesia. The rTPA solution
was prepared by adding 50 mL sterile balanced salt solution
(Alcon Laboratories, Fort Worth, TX, USA) to a vial con-
taining 50 mg of commercially available rTPA (Actilyse;
Boehringer Ingelheim, Ingelheim/Rhein, Germany) using
aseptic technique in a laminar-airflow hood. We then injected
0.1 mL of rTPA solution containing 100 µg rTPA and 0.3 mL
of pure perfluoropropane gas into the vitreous cavity
through a 30 gauge needle via the pars plana in the
inferotemporal quadrant 3 mm to 4 mm posterior to the
limbus. We reduced intraocular pressure by anterior cham-
ber paracentesis before gas injection and, if necessary, again
at the end of the procedure. Patients were instructed to
remain in a supine position for 4 hours to allow the rTPA to
set. Patients were then kept in a face-down position for 4
days to maintain buoyant pressure on the afflicted area.
Efficacy measurement and statistical analysis
Efficacy was estimated according to the degree of
improvement in visual acuity and degree of blood dis-
placement, determined from ophthalmoscopic changes prior
to and after the operation. If more than 90% of the afflicted
area was cleared of blood, displacement was defined as
complete; 20% to 90% clearance was defined as partial
displacement, and less than 20% clearance was defined as
no displacement. In addition, preoperative characteristics,
such as age, gender, time since onset, initial size of
hemorrhage, and initial visual acuity, were also evaluated
for their biologic correlation with vision improvement. The
relationships between preoperative characteristics and
visual outcome were analyzed using the Chi-squared test (if
≤ 5 cells were analyzed, Fisher’s exact test was used). All
analyses were performed using the SAS statistical software
package 8.0 (SAS Institute Inc, Cary, NC, USA); statistical
significance was set at a p value of less than 0.05.
RESULTS
Submacular hemorrhage was identified in only one eye of
each of the 15 patients enrolled in our study (6 in the right
eye and 9 in the left). All patients had signs of ARMD in the
fellow eye, consisting of drusen, geographic atrophy, retinal
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pigment epithelial changes, or choroidal neovascularization.
The average size of the subretinal hemorrhage was 7.4
macular photocoagulation study disc diameters (range,
1.5–20 disc diameters). The mean duration of the pre-
operative lesion was 21.1 days (range, 1–84 days).
Intravitreous injection of rTPA and gas resulted in complete
displacement in 12 eyes (80%) and partial displacement in
three eyes (20%). Normally, despite the size of the hemorrhage,
subretinal blood shifted inferotemporally from the fovea (Figure
1). The fundus photographs for a 58-year-old male patient
with 12 disc diameters of submacular hemorrhage depict the
hemorrhage before treatment and complete displacement after
treatment (Figure 2).
After blood displacement, FA revealed subfoveal CNVM
in six eyes (40%), juxtafoveal CNVM in five eyes (33%), and
no apparent CNVM in four eyes (27%).
No major complications occurred intra- or post-
operatively. Moreover, no evident rTPA-associated retinal
toxicity, such as exudative retinal detachment or retinal
pigment epithelium change, was detected. Although two
patients developed breakthrough vitreous hemorrhage
within 1 day after treatment, both conditions were mild and
the bleeding spontaneously resolved within 2 weeks without
further treatment. Other than that, no marked complications
such as recurrent hemorrhage, elevated intraocular pressure,
lens opacity, or endophthalmitis were observed.
Best postoperative visual acuity improved in all 15 eyes.
Seven eyes (47%) had improvement of two or more lines
and the remaining eight eyes (53%) improved less than two
lines from the baseline. The average time to achieve the best
postoperative visual acuity was 2.1 months (range, 2 weeks
to 4 months). The final visual acuity was 20/100 or better in
Figure 1. Effect of recombinant tissue plasminogen activator (rTPA) and gas treatment on a delayed hemorrhage in an 80-year-old man with 56-
day submacular hemorrhage secondary to age-related macular degeneration. (A) Preoperative fundus photograph shows a blood clot covering the
fovea; (B) 2-week postoperative fundus photograph demonstrates typical displacement of blood inferotemporal to the fovea; (C) initial fluorescein
angiogram reveals a hyperfluorescent juxtafoveal choroidal neovascular membrane (CNVM); (D) fluorescein angiogram 2 weeks after treatment
reveals an underlying subfoveal CNVM lesion.
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six eyes (40%) and 20/200 or better in 10 eyes (67%). When
compared with preoperative visual acuity, the final visual
acuity improved in 12 eyes, remained stable in two eyes,
and worsened in one eye. Improvement of two or more lines
occurred in six eyes (40%). When compared with the best
postoperative visual acuity, the final visual acuity in seven
eyes (47%) was unchanged and that in the other eight eyes
deteriorated. Clinical characteristics are listed in the Table
and the changes in visual acuity at each visit are shown in
Figure 3.
A shorter time since onset of hemorrhage was associated
with a better visual outcome postoperatively (i.e. gain of
lines of vision). That is, when the time since onset was 21
days or less, seven of 10 eyes (70%) improved by two or
more Snellen visual acuity lines, whereas when the time
since onset was more than 21 days, none of five eyes (0%)
showed improvement (p = 0.0256). A similar correlation
was found for improvement in final visual acuity (p =
 0.044). On the other hand, no significant difference was
found between postoperative visual acuity recovery and
clinicopathologic parameters such as hemorrhage size,
preoperative visual acuity, age, and gender.
DISCUSSION
Thick submacular hemorrhage in ARMD is frequently
associated with poor visual recovery regardless of the
treatment method. Several mechanisms have been proposed
for the loss of vision in patients with subretinal hemorrhage,
Figure 2. Effect of recombinant tissue plasminogen activator (rTPA) and gas treatment on a massive submacular hemorrhage (12 disc diameters)
in a 58-year-old man 28 days after onset. (A) Preoperative fundus photograph shows a massive blood clot covering the fovea and the full inferotemporal
quadrant of the posterior pole; (B) fundus photograph 4 weeks after treatment demonstrates complete displacement from the center of the fovea, when
visual acuity had increased from 1/200 to 20/200; (C) preoperative fluorescein angiogram corresponding to (A) shows a hot spot at the nasal margin
of the blood clot; (D) fluorescein angiogram 4 weeks after successful treatment reveals a juxtafoveal choroidal neovascular membrane lesion.
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Figure 3. Changes in visual acuity
(VA) for each patient before and after
treatment. Best postoperative VA
improved in every patient, by two or
more lines in seven eyes (47%) and by
less than two lines in the remaining
eight eyes (53%). The average time to
achieve the best postoperative VA was
2.1 months (range, 2 weeks to 4
months). HM = hand motion.
Table. Clinical characteristics of 15 patients with submacular hemorrhage secondary to age-related macular degeneration
before and after treatment with recombinant tissue plasminogen activator and gas
Gender/Age (yr)/Eye Visual acuity Hemorrhage Follow-up (mo) Complications
Initial Best Final  Disc diameter Duration (d)
M/58/OD 1/200 20/200 20/200 12 28 19
M/71/OD 2/200 20/100 20/200 6 2 19
M/79/OS HM 5/200 1/200 8 4 17
F/60/OS 6/200 20/200 6/200 4 14 19
M/75/OD 3/200 20/200 20/200 20 1 14 VH
F/55/OD 20/40 20/25 20/25 9 7 14.5
M/74/OS 1/200 20/50 20/100 4 7 15 VH
M/80/OS 6/200 20/200 1/200 7 56 15.5
M/60/OS 1/200 20/60 20/100 10 14 15.5
F/67/OD 8/200 20/100 20/100 3 4 10
M/73/OS 20/100 20/30 20/30 4.5 21 9
M/77/OS 1/200 6/200 1/200 8.5 42 7
M/89/OS 20/300 20/200 20/200 3 84 8
M/87/OS 10/200 20/100 20/100 10 5 6.5
F/57/OD 2/200 16/200 10/200 1.5 28 6
OD = L. oculus dexter (right eye); OS = L. oculus sinister (left eye); HM = hand motion; VH = vitreous hemorrhage.
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including photoreceptor shearing by fibrin clot retraction,
physical separation of photoreceptor from the retinal
pigment epithelium, iron toxic effect, and mechanical
blockage of nutrient diffusion [24–27]. Natural history and
experimental data have prompted the search for a safe and
effective method of restoring visual function and of
removing the thick subretinal blood to minimize
neurosensory retinal damage. Currently, two different
therapeutic strategies are used: surgical removal by pars
plana vitrectomy with or without rTPA, and intravitreous
rTPA with gas injection. The results of pars plana vitrectomy
with and without intraoperative rTPA are inconsistent.
Increased retinal damage and other complications have
frequently been reported [1,8–15]. On the other hand, the
management of submacular hemorrhage using intravitreous
rTPA injection and gas displacement effectively displaces
the blood clot and facilitates vision improvement [2,16–23].
Our study confirms these findings. The procedure is easy
to perform, inexpensive, less invasive than vitrectomy,
and results in a successful clinical outcome and few
complications.
Our results indicated that rTPA readily diffused into
the subretinal space and effectively dissolved the blood
clot within 4 hours of reaction time, resulting in vision
improvement. However, the diffusion of rTPA from the
vitreous humor through the neurosensory retina is
not completely understood. Coll et al [28] and Boone
et al [29] found that blood clot lysis of submacular
hemorrhage in rabbits and pigs was visualized 24 hours
after injection of intravitreous rTPA, while saline-treated
eyes demonstrated no change in clot size. Hesse and
coworkers also found blood enlargement in a gravity-
dependent manner 24 hours after intravitreous injection of
rTPA [17]. They concluded that the diffusion of rTPA across
the retina may be explained by retinal microlesions
secondary to subretinal blood clots.
Despite these advantages, the potential retinal toxicity
from commercially available rTPA remains a serious
concern. In animal models, Johnson et al [30] and Hrach et
al [31] observed dose-dependent retinal toxicity with
intravitreous injection at concentrations of 50 µg/0.1 mL or
greater, including severe retinal necrosis, fundus pigmentary
changes, and loss of photoreceptor elements. Hesse et al
also reported exudative retinal detachment, retinal pigment
epithelium hyperpigmentation, and a marked reduction in
the electroretinalgram in eyes that received 100 µg but not
in eyes treated with 50 µg [23]. However, Hassan and
colleagues found no retinal or other intraocular toxic
reactions to rTPA in the doses used in their study (25–
100 µg) [20]. Hattenbach et al [18] and Handwerger et al [19]
found no evidence of retinal or other intraocular toxic
reactions using a dose of 50 µg. In fact, the safe and effective
dose is currently unknown. In our study, most patients had
thick hemorrhage with a relatively large disc diameter
(mean, 7.4) and the time since onset of hemorrhage was
relatively long (mean, 21.1 days). Therefore, we chose 100 µg
rTPA as an optimal dose. Our study found no evidence of
retinal or other intraocular toxic reactions to rTPA solution
(100 µg/0.1 mL). Specifically, no retinal pigmentary changes
outside areas of previous submacular hemorrhage and no
unexplained visual acuity or visual field loss were found.
In light of the potentially damaging effects of
intravitreous rTPA, several investigators have suggested
that the intravitreous injection of gas alone may be effective
in displacing submacular hemorrhage. Ohji and coworkers
documented the beneficial effects of gas without rTPA on
the vision of patients with submacular hemorrhage [32].
However, in their study, intravitreous gas alone failed to
produce displacement in two of four ARMD cases. Moreover,
one of the two patients with no displacement had a symptom-
to-treatment interval of 18 days and the remaining three
patients had durations of 4 to 6 days. The authors speculated
that solid blood clots for more than 1 week may not be
displaced with gas compression alone. However, even a
freshly formed clot may tightly adhere to the photoreceptor
outer segment and to the retinal pigment epithelium. Thus,
direct mechanical manipulation of the clot without clot
lysis, for example pneumatic displacement alone, might
increase retinal damage. Furthermore, even if clots are
successfully displaced from the fovea, they may still damage
the overlying photoreceptor and retinal pigment epithelium
if they are not lysed. In our study, visual acuity improved in
all patients and no new visual field defects occurred after
displacement of the lysed blood clot. Although 20% of
patients had partial displacement, rTPA-induced blood clot
lysis facilitated the absorption of the blood clot. Therefore,
we believe that a combined injection of rTPA and gas is
more effective than injection of gas alone.
Identification of CNVM in ARMD is important. In our
study, post-treatment FA revealed subfoveal CNVM in six
eyes (40%) and juxtafoveal CNVM in five eyes (33%). Of
these 11 patients, five underwent laser photocoagulation
for subfoveal CNVM and three for juxtafoveal CNVM
because photodynamic therapy was not available in our
hospital when this study was conducted. The CNVM was
not identified in four eyes because of partial displacement
of blood and disciform scar formation that obscured the
underlying CNVM.
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Overall, eyes with a shorter time since onset of hemorrhage
tended to have more favorable results, including better gain of
lines in best postoperative vision and better improvement in
final visual acuity. Among the 10 eyes with onset of hemorrhage
within 21 days, seven (70%) improved by two or more Snellen
lines to their best postoperative visual acuity, compared with
none of five eyes (0%) with hemorrhage onset more than 21
days before presentation (p = 0.0256). By the end of the follow-
up period, six eyes (60%) with hemorrhage onset within 21
days had gained two or more Snellen lines, whereas none of
five eyes (0%) with onset more than 21 days previously had
(p = 0.044). These results suggest that time since onset of
hemorrhage is a potential predictor of vision recovery after
treatment with intravitreous injection of rTPA and gas in
ARMD patients. Hattenbach et al also found that duration
of hemorrhage was associated with visual results [18]. How-
ever, in contrast with our results, they concluded that duration
of hemorrhage of 14 days or less was the predictor of vision
recovery. The different results may be explained by the differ-
ent dose of rTPA: Hattenbach et al used 50 µg rTPA while
we used 100 µg. We thought a higher dose of rTPA would be
needed for longer durations of hemorrhage to achieve suffi-
cient clot lysis. Further research to establish the optimal dose
for various durations of hemorrhage is needed.
All the patients in our study experienced vision im-
provement coincident with or soon after displacement of
blood from the fovea. Some patients, particularly those with
limited vision in the fellow eye, reported that this prompt
recovery of central vision significantly enhanced their ability
to perform daily tasks. However, in eight patients, this benefit
was only temporary because subsequent retinal pigment
epithelial atrophy, disciform scar, and revascularization
developed, leading to a deterioration of vision to within two
lines of pretreatment visual acuity.
In summary, we conclude that intravitreous injection of
rTPA and gas is effective in displacing submacular
hemorrhage, facilitating vision improvement, and treating
CNVM in most cases. The procedure is simple, inexpensive,
and results in few complications. Although the final visual
outcome is often limited by progression of ARMD, significant
and stable visual recovery over an extended follow-up
period is possible.
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